WO2000027224A1 - Produits alimentaires favorables a la sante - Google Patents

Produits alimentaires favorables a la sante Download PDF

Info

Publication number
WO2000027224A1
WO2000027224A1 PCT/JP1999/006238 JP9906238W WO0027224A1 WO 2000027224 A1 WO2000027224 A1 WO 2000027224A1 JP 9906238 W JP9906238 W JP 9906238W WO 0027224 A1 WO0027224 A1 WO 0027224A1
Authority
WO
WIPO (PCT)
Prior art keywords
genus
health
ebine
angelica
plant belonging
Prior art date
Application number
PCT/JP1999/006238
Other languages
English (en)
Japanese (ja)
Inventor
Manabu Nomura
Original Assignee
Manabu Nomura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Manabu Nomura filed Critical Manabu Nomura
Priority to AU11765/00A priority Critical patent/AU1176500A/en
Publication of WO2000027224A1 publication Critical patent/WO2000027224A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)

Definitions

  • the present invention relates to a health supplement that utilizes the excellent disease-ameliorating effect and health-retaining function of the genus Umbelliferae of the Umbelliferae family.
  • euphoria As representatives of the cedars of the genus Apiaceae, commonly referred to as euphoria, euphorbia, inu genus, and hyuga touki (hereafter, euphoria) have been known.
  • Hyuga-Tuki the disease ameliorating effect and the health maintenance function of Hyuugatsuki have not been verified so far.
  • the present inventor has focused on the pharmacological activity of Inu-Toki, and as a result of diligent research on the plant of the same genus, Hyuga-Tuki, various types of Hyuga-Tuki that are superior to Inu-Tuki are shown. It was found to have pharmacological effects and was found to be useful as a dietary supplement.
  • the present inventor has found that by adding the ebine to the eucalyptus, the amelioration of the illness peculiar to the eucalyptus and the further improvement of health can be achieved. It has been found that a holding function can be obtained.
  • the present invention is based on such findings, and has an object to provide a natural plant-derived safe dietary supplement having an excellent disease ameliorating effect and a health maintaining function. Disclosure of the invention
  • the health supplement of the present invention which has achieved the above object, is characterized in that a processed product of the genus Hydrangea sp.
  • the health supplement of the present invention is characterized in that a mixture of a processed product of a plant belonging to the genus Apiaceae and a processed product of a plant belonging to the genus Ebine belongs to the active ingredient.
  • typical examples of plants belonging to the genus Shishido of the Umbelliferae family include Hyugata (An gelicaacutiloba), Inuuki (An gelicashicokiana), and Hyugata (Angelicatenuisecta), which is one of the strains of the genus Azenica (An gelicatenuisecta). Ki (A. furcijugakitag.).
  • Hyugatuki Ange 1 icafurcijuga K itagawa
  • Umb elliferae genus Apiaceae
  • Ansi 1 L.
  • Hyugatoki has excellent pharmacological action itself as compared with Toukijinuki, and can be used as a health supplement food useful for various diseases and health maintenance.
  • s-GOT serum transamylase
  • s-GOT serum transamylase
  • Jebine type Jebine (C. discolor), Kiebine (C. sieboldii), Kirishima ebine (C. aristu 1 ifera), Amamiebine (C. amamiana), and Nyoebine (C. izu-insularis) tricarinata), C. tokunoshimaensis, C. arisanensis, C. graciliflora, C. p1 antaginea or C. p 1 antaginea or C. ), Togaribaebine (C. caudatilabella).
  • Tin flea vine type C. 1 iukiuen sis
  • Tamazakiebine C. densiflora
  • Bulkura C. pu 1 chra
  • Taganelan type Taganelan (C. bungoana), Whiteana (C. whiiteana).
  • Sakurajima shrimp type Sakurajima shrimp (C.ob1ancceo1ata, mannii (C.mannii)).
  • Kisoebine type Kisoebine (C. schlecchtteri), Alpina (C. a1pina).
  • Hiro no nokaran type Hiro no nokaran (C. jap0nica).
  • Natsuebine type Natsuebine (C. ref f1exa).
  • Turran types Turran (C. furcata), Onagae Bine (C. longicalcarata), Okinadjebine (C. okinawaensis), Trout sword (C. ma suca), Mag sword (C. madagascariensis), Natalensis (C. natalensis).
  • Toxalan type Toxalan (C. venusta), white toxalan (C. longipes), biloba (C. bi1oba).
  • the processed product is a dry powder, a small piece, a frozen powder, a pressed product, a pressed product of a corn or ebine. Juices, extracts, extracts, etc. What is processed by such means widely means. It also includes granulation using powder, granules, capsules, and the like.
  • Fig. 1 is a table showing the inhibitory effect of the processed product and its components on D-Ga1N / LPS-induced hepatic injury in mice
  • Fig. 2 is a first-generation cultured rat liver using a compound containing a hyugatouki
  • FIG. 3 is a table showing the effect of the components of Hyuuga-touki on D-Ga1N-induced hepatotoxicity in cells.
  • FIG. 3 shows the nitric oxide production inhibitory activity of the compounds containing Hyuga-gatouki on the activation of intraperitoneal macula phage in mice.
  • Fig. 1 is a table showing the inhibitory effect of the processed product and its components on D-Ga1N / LPS-induced hepatic injury in mice
  • Fig. 2 is a first-generation cultured rat liver using a compound containing a hyugatouki.
  • FIG. 3 is a table showing the effect of the components of Hyuuga-touk
  • Fig. 4 is a table showing the health supplement function of Hyugatuki alone extract and a mixed extract of Hyugatuki and Ebine
  • Fig. 5 is a chart of Ginseng alcohol extract and Isoepoxybuterixin.
  • a graph showing the inhibitory effect of skin tumor on CD-1 mice. (A) shows the number of mice with tumors, and (mouth) shows the number of tumors per mouse. Show. BEST MODE FOR CARRYING OUT THE INVENTION
  • Hyugatuki which is an active ingredient of the dietary supplement according to the present invention, uses cultivated seeds, wild flowers, roots, stems, leaves, branches, and the like. Usually, it is used as a solid, such as a powder, but it can also be used as a liquid, such as an extract or pressed juice. Additives, excipients, etc. may be added to form granules, tablets, capsules and the like. Sweetening agents, such as stevia, can be added in small amounts to facilitate ingestion. In addition, vitamins commonly used in health supplements may be added.
  • the plant When used as a solid, the plant is freeze-dried or air-dried to powder.
  • the powdered product may be formed into granules, granules, pellets and the like.
  • the plant may be fragmented and dried without powdering, and used as it is. Further, a powder can be obtained by distilling a liquid component from the extract or the squeezed juice.
  • extraction or squeezing is usually used.
  • water or alcohol is used as an extraction solvent. It is common to use a mixed solution of water and alcohol, and its concentration is 10 to 100%, preferably 40 to 80% .
  • alcohol It is desirable to adjust the concentration of the aqueous solution to 25% or less.
  • the mud adhering to the rhizome is dropped and the whole plant is washed with water. Next, it is roughly cut with a cutter, mixer, etc., and squeezed with a press. Compression pressure of the press is 5 0 0-5 may be set to approximately 0 0 0 kg Z cm 2.
  • the squeezed juice can be used as is, or purified or diluted.
  • first fraction 6.6 g (0.17%), second fraction 17.7g (0.49%), third fraction 25.0 g (0.69%), respectively.
  • the water-eluting part and the first fraction were primary metabolites such as saccharides and amino acids based on thin layer chromatography studies.Therefore, the second fraction was subjected to normal-phase and reverse-phase silica gel chromatography.
  • D-galactosamine D-Ga1N 350 mg / kg and lipopolysaccharide (LPS) 10 ⁇ g / kg intraperitoneally using 25-27 g ddy female mice Injection induced liver damage.
  • LPS lipopolysaccharide
  • Each test sample was given 1 hour prior to D-GaI N / L PS injection. Blood collection was performed 10 hours after D-Ga1N / L PS injection. Each value indicates the average value by S.E.M (p ⁇ 0.05, p ⁇ 0.01).
  • FIG. 1 shows the dose and the serum transaminase activity value (s-GPT, s-GOT) of each sample.
  • Test Example 2 Protective action against D—Ga1N-induced cytotoxicity
  • the hepatoprotective effect of the extract of Hyugatuki was determined using primary cultured hepatocytes using 3 — (4,5-dimethylthiazol-2-yl) — 2-, 5-diphenyltetrazolazole bromide (MTT) colorimetric assay. It was measured by. Hepatocytes were isolated from male diaster rats (130-160 g) by the collagen spray method.
  • Inhibition rate (%) ⁇ (Sample OD—Control group OD) ⁇ (Normal group ⁇ . D—Control group OD) ⁇ Test example 3 (Anti-inflammatory pharmacological activity)
  • mice Male ddy mice (body weight about 30 g) were euthanized by cervical dislocation, and 6-7 ml of buffered saline (PBS) was injected into the abdominal cavity and gently massaged. The obtained peritoneal exudate was washed with PBS and then with RPMI 11640 (containing 10% fetal calf serum, 100 units / ml penicillin, 100 gZml and streptomycin) medium. 5 ⁇ 10 5 cells / 100 ⁇ l of cells were added per well to a 96-well flat bottom microplate, and the cells were cultured at 37 ° C. in a 5% carbon dioxide gas / 95% air atmosphere for 1 hour.
  • PBS buffered saline
  • the suspended cells are washed with PBS, and 200 ⁇ l of lipopolysaccharide (from Sigma, derived from Salmonella enteridisis) containing l O / xg / ml and a test substance is added to the above culture solution, and then added to the culture medium. Cultured for hours. Add 100 g of culture supernatant to a grease reagent (1% (Luphanilamide and 0.1% N-1-naphthylethylenediamine dihydrochloride dissolved in 2.5% phosphoric acid) were added, and the mixture was allowed to stand at room temperature for 10 minutes. The absorbance was measured using a microplate reader (measurement wavelength: 562 nm, control wavelength: 630 nm). The amount of NO— accumulated in the culture broth using sodium nitrite as a standard substance was determined as the amount of NO produced.
  • phalkanol, phalkanoldiol, and disoepoxybuterixin obtained in Examples were used, and hydrocortisone was used as a control drug known to have an anti-inflammatory effect.
  • the results are shown in FIG.
  • serum transaminase activity s-GPT, s-GOT
  • s-G ⁇ ⁇ were significantly suppressed in the groups administered with the substances derived from Hyuga-touki, including pharmacaldiol.
  • MTT assay method is a cell counting method that utilizes the fact that yellow MTT changes to magenta formazan by cell dehydrogenase.
  • iso-epoxybuterixin exhibited a concentration-dependent hepatocyte protective effect.
  • falcarindiol on the contrary, showed toxicity to hepatocytes.
  • Isopteryxin was found to have a protective effect as another minor component.
  • macrophage activation was suppressed by using the amount of nitric oxide (NO), which is produced by the activation of macula phage by LPS. Since NO is that changes to NO 2 immediately oxidized, it was considered as the amount of N_ ⁇ the amount of NO 2 in the culture solution.
  • NO nitric oxide
  • isoepoxybuterixin and phalkariandiol strongly inhibited NO production at a concentration that was not cytotoxic to macrophages.
  • Anomalin (anoma1 inn), benoregapten (bergapten), cellabshanin (servashchanin), and isopterixin, a novel compound, telentacin A, also exhibited an inhibitory effect, and particularly strong activity of falcarindiol was observed.
  • pharmacandiol strongly suppresses the activation of macrophages, and is considered to have suppressed this liver injury.
  • isoepoxybuterixin not only exerts hepatoprotective action by acting on the liver side, but also suppresses D-Ga1N / IPS-induced liver damage by suppressing macrophage activation. .
  • Test Example 4 Anti-tumor pharmacological activity
  • mice Female CD-1 in experimental animals? Groups of 88-week-old mice were grouped into 20 mice. Two days before the experiment, mice with shaved hair and a hair resting period were used. All samples were dissolved in acetone and applied with 0.2 ml of micropipette to shaved skin. First, dimethylbenzenanthracene (DMBA) 200 nm 01 was applied to mouse skin as an initiator of carcinogenesis. Ten days later, 5 nmol of tetradecanol phorbol-13-acetate (TPA) was applied twice a week, and the treatment was continued for 18 weeks. The samples were applied twice a week at the same time as the TPA application and continued for 18 weeks.
  • DMBA dimethylbenzenanthracene
  • TPA tetradecanol phorbol-13-acetate
  • health supplements containing as an active ingredient a mixture of a processed product of a plant belonging to the genus Umbelliferae and a processed product of a plant belonging to the genus Ebine belong to the processed products of the ibis and ebine.
  • the composition ratio of ebine is preferably 4 to 2 with respect to 6 to 8 of eucalyptus. If the mixing ratio of ebine is high, it is highly irritating and difficult to ingest.
  • the addition of vinegar, especially black vinegar significantly enhances the function of dietary supplements. It is desirable to adjust the pH of the mixed solution to about 3 to 5 by adding vinegar from the viewpoint of improving storage stability.
  • sweeteners such as stevia may be added in small amounts to facilitate ingestion.
  • the addition of vitamins commonly used in health supplements is optional.
  • This mixed dietary supplement of eucalyptus and ebine is usually provided as a liquid beverage consisting of squeezed juice or extract. They can also be provided in granules, tablets, and capsules. Additives, excipients, etc. can be added to the squeezed juice or extract to form granules, tablets, capsules and the like.
  • the daily intake should be 10 to 30 ml Z 2 to 3 times as a normal liquid health supplement.
  • the health supplement of the present invention can be produced, for example, as follows. First of all, as the raw materials, all vegetation such as leaves, stems, flowers, and roots can be used for the ibis and ebine, but the root is particularly preferable. In both cases, the whole plant is washed with water, and cut with a cutter or mixer. Next, 2 kg of the roughly cut and dried oysters are cooked at a rate of 20 liters of water. On the other hand, 1 kg of ebine is water 10 Cook at a little rate. Pressed juice may be used, but cook over low heat until the volume is reduced to about 1/3. Usually takes 4-5 hours. After boiling, allow to cool to room temperature, filter and mix. The mixture is desirably added with 5 to 15% of black vinegar to adjust the pH to about 3 to 5. Add an appropriate amount of sweetener, such as stevia, to make it easier to drink.
  • sweetener such as stevia
  • Hyugatuki native to southern Miyazaki prefecture was used.
  • the leaves, stems, roots, and other whole plants were washed with water and roughly cut with a power cutter.
  • 2 kg of the dried and dried hyuugatsuki was boiled with 20 liters of water. Finally, they cooked on low heat until the capacity was about 1/3. The boiling time was 4 hours. After boiling, the mixture was allowed to cool to room temperature, and the solid was filtered off. About 10% of the total amount of black vinegar was added to the mixture, and the pH was adjusted to 4. A small amount of stevia was added to this as a sweetener.
  • Hyugatuki native to southern Miyazaki prefecture was used for corn, and Jebine native to southern Miyazaki prefecture was used for ebine. All leaves, stems, The whole plant, including the roots, was washed with water and roughly cut with a power cutter. 2 kg of the dried and dried hyuga touki was boiled with 20 liters of water. 1 kg of the coarsely cut Jebine was boiled with 10 liters of water. Finally, they cooked on low heat until the capacity reached about 13. The boiling time was 4 hours. After boiling, the mixture was allowed to cool to room temperature, and solids were separated by filtration and mixed. About 10% of the total amount of black vinegar was added to the mixture, and the pH was adjusted to 4. A small amount of stevia was added to this as a sweetener. Control Example 1
  • FIG. 4 qualitatively shows the disease improving function and the health maintenance function of the samples shown in Examples 1 and 2 and Control Examples 1 and 2.
  • the anticancer effects of corns include isepoxyshibuterixin, which is a new coumarin, terantacoside A, a turpentine KB, a new coumarin glycoside, turpentine I, The lactone in the coumarin skeleton is found in the ring-opened new compound telternacide ⁇ and the new lignan tetancoside m.
  • anti-cancer effects have also been recognized on ebine, which has long been known as a specific drug for uterine diseases.
  • Example of anti-hepatitis action The anti-hepatitis action as a citrus extract is known in Japanese Patent Application Laid-Open No. Hei 4-33665. It is also found in the contained falcarin diol and isoepoxybuterixin.
  • Example of anti-inflammatory action The anti-inflammatory action as a rubrum extract is also known in Japanese Patent Publication No. 5-48233, but according to the knowledge of the present inventors, it is known that the alkanol contained in rubbles contains , And also found in phthalic diols.
  • Example of anti-allergic action It is known in Japanese Patent Publication No. 5-482333 that iso-epoxybuterixin containing turkeys has anti-inflammatory and anti-allergic activity. Further, according to the findings of the present inventors, indirubin and tryptatrin contained in ebine have a strong antiallergic action, and also have an action as an antitopy, an antidandruff agent, an antibacterial agent and the like. Is recognized.
  • Example of anti-diabetic action The anti-diabetic action as a eucalyptus extract is also known in Japanese Patent Application Laid-Open No. 7-530600, but according to the knowledge of the present inventors, it is also recognized in falcarindiol contained in eucalyptus. .
  • vasodilatory action as an extract of eucalyptus is disclosed in Japanese Patent Application Laid-Open No. 4-33665, and the isoepoxybuterixin contained in eucalyptus is disclosed in Japanese Patent Application Laid-open No. Hei 7-53560.
  • strong vasodilatory action is also observed for Ebine.
  • Example of anti-hyperlipidemic action The anti-lipidemic action as a turkey extract is known from Japanese Patent Publication No. 4-33365. Industrial availability
  • the hyugatuki of the present invention contains a large number of pharmacologically active substances and, for example, suppresses an anticancer effect and an antihepatitis effect and can be widely used as a health supplement.
  • hyugatuki is a natural plant with no side effects and can be taken for a long time with confidence.
  • a mixture comprising a squeezed juice and an extract of the corns and ebine of the present invention
  • a health supplement for example, anti-cancer, hepatitis treatment, anti-inflammatory, anti-allergy
  • It can be expected to have various uses such as diseases, diabetes, vasodilation, treatment of hyperlipidemia, prevention of arteriosclerosis, and stamina. It is especially effective as a health supplement with anti-cancer and anti-hepatitis effects with a low recurrence rate.
  • both ibis and ebine are naturally occurring plants, have no acute toxicity and can be taken safely for a long period of time. Therefore, they are suitable for daily health maintenance such as improvement of chronic diseases and lifestyle-related diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne des produits alimentaires favorables à la santé qui contiennent comme principe actif des produits traités issus de l'umbelliferae angelica furcijuga, ainsi que des produits alimentaires favorisant la santé contenant comme principe actif des mélanges de plantes de la famille de l'umbelliferae angelica et des plantes de la famille de l'orchidaceae calanthe. Par exemple, des plantes entières séchées (feuilles, pédoncules, racines, etc.) d'angelica et de calanthe sont lavées à l'eau et hachées grossièrement avec un couteau. 2 kg de parties d'angelica sont mis à bouillir dans 20 l d'eau et 1 kg de partie de calanthe est mis à bouillir dans 10 l d'eau. Ces mélanges mijotent à feu doux afin de réduire le volume d'eau à 1/3. Après ébullition et refroidissement à température ambiante, ces mélanges sont filtrés et associés. On ajoute entre 5 et 15 % de vinaigre de vin au mélange obtenu afin d'ajuster le pH entre environ 4 et 5. Puis on ajoute un volume approprié d'édulcorant. L'extrait ainsi obtenu présente les effets bénéfiques de l'angelica qui permettent d'améliorer certaines pathologies (effet anticancéreux, effet anti-inflammatoire, etc.), ainsi que l'effet antibactérien et l'effet anti-inflammatoire de la calanthe, ce qui permet d'obtenir des produits favorisant la santé comme jamais auparavant.
PCT/JP1999/006238 1998-11-11 1999-11-10 Produits alimentaires favorables a la sante WO2000027224A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU11765/00A AU1176500A (en) 1998-11-11 1999-11-10 Health-promoting foods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10/319712 1998-11-11
JP31971298 1998-11-11

Publications (1)

Publication Number Publication Date
WO2000027224A1 true WO2000027224A1 (fr) 2000-05-18

Family

ID=18113344

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1999/006238 WO2000027224A1 (fr) 1998-11-11 1999-11-10 Produits alimentaires favorables a la sante

Country Status (2)

Country Link
AU (1) AU1176500A (fr)
WO (1) WO2000027224A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872409B2 (en) * 2001-10-17 2005-03-29 Braingenesis Biotechnology Co., Ltd. Composition of traditional chinese medicines for preventing and treating cerebrovascular disease
JP2006515314A (ja) * 2003-04-22 2006-05-25 ラボラトリオ キミコ インターナショナール ソシエタ ペル アチオネ チオクト酸のｌ−カルニチンとの塩基性塩
JP2008125454A (ja) * 2006-11-22 2008-06-05 Manabu Nomura 健康補助食品およびその製造方法
WO2012004875A1 (fr) * 2010-07-08 2012-01-12 株式会社河野メリクロン Nouvelle substance séparée d'une orchidée, et extrait, antioxydant, agent antibactérien, agent anti-cancer et agent anti-inflammatoire la contenant
JP2012102068A (ja) * 2010-11-13 2012-05-31 Showa Univ 皮膚および毛髪の黒化促進剤、その黒化促進剤を含む黒化促進用外用剤および黒化促進用飲食品
JP2015003874A (ja) * 2013-06-20 2015-01-08 株式会社エレガントジャパン シクロオキシゲナーゼ活性阻害剤及び該シクロオキシゲナーゼ活性阻害剤を含有する組成物
CN104352796A (zh) * 2014-12-03 2015-02-18 张福国 一种治疗正畸牙龈炎的药物组合物
JP2015038117A (ja) * 2014-10-06 2015-02-26 学校法人昭和大学 皮膚および毛髪の黒化促進剤、その黒化促進剤を含む黒化促進用外用剤および黒化促進用飲食品
JP6095823B1 (ja) * 2016-03-24 2017-03-15 株式会社かめいあんじゅ 漬物用調味液およびそれを用いた漬物、並びに容器入り漬物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH043365B2 (fr) * 1984-06-07 1992-01-23
JPH0548233B2 (fr) * 1986-12-12 1993-07-20 Nippon Yamaninjin Kenkyusho Kk
JPH10139676A (ja) * 1996-11-07 1998-05-26 Manabu Nomura 抗アレルギー性皮膚外用組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH043365B2 (fr) * 1984-06-07 1992-01-23
JPH0548233B2 (fr) * 1986-12-12 1993-07-20 Nippon Yamaninjin Kenkyusho Kk
JPH10139676A (ja) * 1996-11-07 1998-05-26 Manabu Nomura 抗アレルギー性皮膚外用組成物

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872409B2 (en) * 2001-10-17 2005-03-29 Braingenesis Biotechnology Co., Ltd. Composition of traditional chinese medicines for preventing and treating cerebrovascular disease
JP2006515314A (ja) * 2003-04-22 2006-05-25 ラボラトリオ キミコ インターナショナール ソシエタ ペル アチオネ チオクト酸のｌ−カルニチンとの塩基性塩
JP4688502B2 (ja) * 2003-04-22 2011-05-25 ラボラトリオ キミコ インターナショナール ソシエタ ペル アチオネ チオクト酸のｌ−カルニチンとの塩基性塩
JP2008125454A (ja) * 2006-11-22 2008-06-05 Manabu Nomura 健康補助食品およびその製造方法
WO2012004875A1 (fr) * 2010-07-08 2012-01-12 株式会社河野メリクロン Nouvelle substance séparée d'une orchidée, et extrait, antioxydant, agent antibactérien, agent anti-cancer et agent anti-inflammatoire la contenant
JP2012102068A (ja) * 2010-11-13 2012-05-31 Showa Univ 皮膚および毛髪の黒化促進剤、その黒化促進剤を含む黒化促進用外用剤および黒化促進用飲食品
JP2015003874A (ja) * 2013-06-20 2015-01-08 株式会社エレガントジャパン シクロオキシゲナーゼ活性阻害剤及び該シクロオキシゲナーゼ活性阻害剤を含有する組成物
JP2015038117A (ja) * 2014-10-06 2015-02-26 学校法人昭和大学 皮膚および毛髪の黒化促進剤、その黒化促進剤を含む黒化促進用外用剤および黒化促進用飲食品
CN104352796A (zh) * 2014-12-03 2015-02-18 张福国 一种治疗正畸牙龈炎的药物组合物
JP6095823B1 (ja) * 2016-03-24 2017-03-15 株式会社かめいあんじゅ 漬物用調味液およびそれを用いた漬物、並びに容器入り漬物
JP2017169490A (ja) * 2016-03-24 2017-09-28 株式会社かめいあんじゅ 漬物用調味液およびそれを用いた漬物、並びに容器入り漬物

Also Published As

Publication number Publication date
AU1176500A (en) 2000-05-29

Similar Documents

Publication Publication Date Title
Lin et al. Cordyceps as an herbal drug
WO1997033593A1 (fr) Produit obtenu par traitement thermique d'acide uronique, et aliments, boissons ou medicaments contenant ce produit
JP2003192605A (ja) リパーゼ阻害剤
KR20030041813A (ko) 활성산소 소거능 저감 억제제
WO2000027224A1 (fr) Produits alimentaires favorables a la sante
KR20140017932A (ko) 탱자 발효물에 의한 비만개선효과물질의 조성
KR101611853B1 (ko) 항염증 활성이 우수한 섬쑥부쟁이 분획물 및 이로부터 분리된 활성화합물
JPWO2002062365A1 (ja) フェノール類含有シソ科植物エキスの製造法及びその用途
CN110679824A (zh) 一种生鲜面保鲜剂及其制备方法
KR101491493B1 (ko) 감귤 과피 및 구아바 추출물을 포함하는 항염증 약학 조성물
KR102368892B1 (ko) 약난 및 진득찰 추출물을 포함하는 항염증 조성물
KR101207239B1 (ko) 천문동 추출물로부터 제조한 분획물을 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 조성물
KR102248059B1 (ko) 청보리 추출물 또는 이의 분획물을 포함하는 항염증 또는 미백용 조성물 및 이의 용도
KR101636608B1 (ko) 산수유 추출물을 포함하는 항산화용 조성물
KR20220067467A (ko) 몰로키아 추출물을 유효성분으로 포함하는 알코올성 간 손상 개선, 예방 또는 치료용 조성물
KR101769774B1 (ko) 종양 예방 또는 개선용 건강기능성 식품
KR101514284B1 (ko) 땃두릅나무 추출물 또는 이의 분획물을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
KR100590726B1 (ko) 목질진흙버섯 추출물 또는 이로부터 분리된 페린신 에이를유효성분으로 포함하는 심장순환계 질환의 예방 및 치료용조성물
KR20150072659A (ko) 청미래 추출물을 포함하는 간 보호용 조성물
KR102496752B1 (ko) 알코올성 간 손상 예방 기능성 성분을 포함하는 오가피 추출물 및 그 제조 방법
KR20120031706A (ko) 초고압을 이용한 더덕 추출물의 제조방법
KR102483814B1 (ko) 파래 오일을 유효성분으로 포함하는 항균 및 항염증용 조성물
KR102093817B1 (ko) 면역기능 증진 활성이 있는 연잎 유래 다당 분획물 및 이의 제조방법
KR102281794B1 (ko) 황칠 추출물을 유효성분으로 함유하는 중금속에 의한 간손상 보호용 조성물
KR20130058388A (ko) 발효 맥문동 추출물을 유효성분으로 포함하는 항산화 조성물

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 11765

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642